



H.E.L.L.A.S.

HELLENIC SOCIETY OF INFECTIONS IN CRITICALLY ILL PATIENTS

Endorsed by:



Hellenic Society of  
Intensive Care Medicine

# Webinar

Innovations  
in sepsis and  
severe infections



14th  
NOV  
2024

17.00-20.00

Final Program

# General Information

The scientific event will be held online and broadcasted live.

## Date

Thursday, 14 November 2024

## Official Language

The official language of the conference will be English. All informative material and presentations will be in English. No simultaneous interpretation in other languages will be provided.

## Registration Fee

The registration is free of charge.

- Includes access to the seminar's online platform
- Attendance of the scientific program
- Scientific program (digital form)
- Certificate of attendance (e-Certificate)

## Webinar Secretariat



[www.congressworld.gr](http://www.congressworld.gr)



# Greetings

On behalf of the organizing team, I am delighted to welcome you our webinar on “**Innovations in Sepsis and Severe Infections**” We are thrilled to have such a diverse group of participants joining us, from healthcare professionals and researchers to policymakers and innovators. Your presence here today underscores the importance of advancing our understanding and treatment of sepsis and severe infections—conditions that continue to pose significant challenges to global health.

Over the course of this webinar, we will explore cutting-edge research, breakthrough technologies, and novel approaches aimed at improving outcomes for patients facing sepsis and other life-threatening infections. We are fortunate to have a distinguished panel of experts who will share their insights on the latest innovations in diagnostics, treatment strategies, and preventive measures.

Sepsis remains one of the leading causes of death worldwide, and the need for innovative solutions has never been more urgent. Through collaboration and the exchange of knowledge, we can continue to make strides in combating these complex and often devastating conditions.

We encourage you to engage with our speakers, ask questions, and share your thoughts throughout the session. We hope that this webinar will not only provide valuable insights but also inspire new ideas and partnerships in the fight against sepsis and severe infections.

Thank you for being part of this important conversation. Let’s make the most of today’s event and work together toward a healthier future.

Once again, welcome, and we look forward to a productive and enriching session.

Best regards,  
Professor George Dimopoulos




# Program

14 November 2024

16.55-17.00	<b>Welcome and Introduction</b>	G. Dimopoulos
17.00-18.00	<b>Bacterial infections in critically ill</b>	Moderator: Prof. G. Dimopoulos
17.00-17.15	<b>CAP: Corticosteroids for all ?</b>	M. Niedermann
17.15-17.30	<b>Antibiotics' PK/PDs: how to use them bedside</b>	D. Nicolau
17.30-17.45	<b>Eravacycline to fight Acinetobacter spp</b>	G. Dimopoulos
17.45-18.00	<b>Q&amp;As</b>	
18.00-19.00	<b>Fungal infections: what is the newer ?</b>	Moderator: Prof. C. Gogos
18.00-18.15	<b>Resistance to azoles: It is a problem ?</b>	P. Verweij
18.15-18.30	<b>Immunomodulatory effects of antifungals</b>	H. Sambatakou
18.30-18.45	<b>Amphotericin B in the era of new antifungals</b>	K. Akinosoglou
18.45-19.00	<b>Q&amp;As</b>	
19.00-20.00	<b>Sepsis: what is the newer ?</b>	Moderator: Prof E. J. Giamarellos-Bourboulis
19.00-19.15	<b>Angiotensin II</b>	S. Mentzelopoulos
19.15-19.30	<b>Precision immunotherapy</b>	E.J. Giamarellos-Bourboulis
19.30-19.45	<b>Precision medicine using physiometers</b>	V. Papaioannou
19.45-19.55	<b>Q&amp;As</b>	
19.55-20.00	<b>Closing Remarks</b>	





# VABOREM<sup>®</sup>

meropenem/vaborbactam



#### ΠΟΙΟΤΙΚΗ ΚΑΙ ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ:

Κάθε φιαλίδιο περιέχει τριυδρική μεροπενέμη ισοδύναμη με 1g μεροπενέμης και 1 g βαμπορβακτάμης. Μετά την ανασύσταση, 1ml του διαλύματος περιέχει 50mg μεροπενέμης και 50 mg βαμπορβακτάμης.

**ΤΡΟΠΟΣ ΔΙΑΘΕΣΗΣ:** Χορηγείται με περιορισμένη ιατρική συνταγή, μόνο για νοσοκομειακή χρήση.

**ΤΡΟΠΟΣ ΧΟΡΗΓΗΣΗΣ:** Μέσω ενδοφλέβιας έγχυσης επί 3 ώρες.  
Π.Χ.Π. VABOREM<sup>®</sup>: Ημερομηνία αναθεώρησης του κειμένου, 07/2023

ΠΕΡΙΕΚΤΙΚΟΤΗΤΑ

PD.C.S.INF (1+1)G/VIAL

ΝΟΣΟΚΟΜΕΙΑΚΗ ΤΙΜΗ

346,33€

Πριν τη συνταγογράφηση, για πλήρεις συνταγογραφικές πληροφορίες και πληροφορίες σχετικά με την ασφάλεια και ανεκτικότητα παρακαλούμε συμβουλευτείτε την Περίληψη Χαρακτηριστικών του Προϊόντος σκανάροντας το QR Code.

Για περισσότερες πληροφορίες και για την πλήρη Π.Χ.Π. παρακαλώ απευθυνθείτε στην εταιρεία:

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και  
Αναφέρετε  
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για  
ΟΛΑ τα φάρμακα  
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»



Menarini Hellas

Menarini Hellas A.E. - Πάτμου 16-18, 151 23 Μαρούσι, Αττική  
Τ.: 210 8316111-13, F.: 210 8317343, info@menarini.gr, www.menarini.gr



 **CRESEMBA<sup>®</sup>**  
(ISAVUCONAZOLE)



**Ρίφizer Ελλάς Α.Ε.**,  
Λ. Μεσογείων 243, Ν. Ψυχικό 15451, Αθήνα, Ελλάδα,  
Τηλ. Επικοινωνίας 210-6785800,  
Αριθ. Γ.Ε.ΜΗ. 000242901000  
**Pfizer Ελλάς Α.Ε. (Cyprus Branch)**  
Λεωφόρος Αθαλάσσης 26, 2018 Λευκωσία, Κύπρος,  
Τηλ : 22817690

Πριν τη συνταγογράφηση συμβουλευθείτε  
την Περίληψη Χαρακτηριστικών του Προϊόντος  
που διατίθεται από την εταιρεία.

**Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και  
Αναφέρετε  
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για  
ΟΛΑ τα φάρμακα  
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»**

# FACULTY LIST

## **Akinosoglou Karolina**

Internist - Infectious Diseases Specialist, Associate Professor in Internal Medicine, Department of Medicine, University of Patras, Greece

## **Dimopoulos George**

MD, PhD, FCCP, FECMM, Professor, Head of 3rd Department of Critical Care, "EVGENIDIO" Hospital, National and Kapodistrian University of Athens (NKUA), Athens, Greece

## **Giamarellos-Bourboulis Evangelos**

Professor of Internal Medicine and Infectious Diseases, Director of the MSc Program on Infectious Diseases, National and Kapodistrian University of Athens, Medical School, Greece, Chairman European Sepsis Alliance

## **Gogos Charalambos**

Professor Emeritus, Medicine, Patras University, Director of Dept. of Medicine/ Infectious Diseases Metropolitan General, Co-chairman of the Hellenic Sepsis Study Group, Greece

## **Mentzelopoulos Spyridon**

MD, PhD, DEAA, EDIC, Professor of Intensive Care Medicine, National and Kapodistrian University of Athens Medical School, Department of Intensive Care Medicine, Evangelismos General Hospital, Greece

## **Nicolau David**

PharmD, FCCP, FIDSA, Chief, Preclinical Development and Commercial Strategies, Center for Anti-Infective Research & Development, Hartford Hospital

## **Niedermann Michael S.**

M.D. Lauder Family Professor in Pulmonary and Critical Care Medicine, Weill Cornell Medicine, Lead Academic and Patient Quality Officer, Division of Pulmonary and Critical Care Medicine, NYP-Weill Cornell Medical Center, USA

## **Papaioannou Vasileios**

Professor of Intensive Care and Computational Medicine, Democritus University of Thrace, Greece Head of ICU at Alexandroupolis Hospital, Greece

## **Sambatakou Helen**

Associate Professor in Internal Medicine and Infectious Diseases, Hippokraton General Hospital of Athens, Greece

## **Verweij Paul**

Professor of clinical mycology, Board member of the Radboudumc-CWZ center of Expertise for Mycology, Director of the national mycology reference laboratory for invasive mycoses, The Netherlands




# Acknowledgements



Menarini Hellas







# Fomicyt<sup>®</sup>

fosfomycin i.v.



FOM/PPA/11-2019/02

From magic bullets to  
**Smart Bullets<sup>\*</sup>**

\* Valent P, J Innate Immun 2016;8:111-120

